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BODY AND MIND
On the Way to
Alzheimer's Disease
Current research
indicates that the onset
of Alzheimer's disease is
preceded by a stage
termed "mild cognitive
impairment." By
recognizing the
characteristics of this
preclinical phase and
administering the proper
treatments, physicians
may be able to stop the
progression toward AD.
Dr. M. Saleem Ismail is Senior
Instructor in Psychiatry at the
University of Rochester. He is also a
Geriatric Psychiatrist and a clinical
research investigator in
neurobehavioral therapeutics at
Monroe Community Hospital in
Rochester, New York.
By M. Saleem Ismail
he search for treat-
ment of Alzheimer's
disease (AD) has
taken a front seat
during the past de-
cade. Demographics and stag-
gering resource utilization' have
added urgency to our efforts in
preventing, diagnosing, and treat-
ing this debilitating illness.
As research in the field of ag-
ing and dementia move forward,
researchers have employed a two-
pronged approach: We not only
need to devise means to identify
individuals who may develop AD,
but we also need to investigate
novel treatment strategies. Many
exciting pharmacological inter-
ventions have been identified,
although we have still not found
a valid diagnostic test to reliably
distinguish AD from other
dementias.
Mild Cognitive Impairment
Recently, a great deal of attention
has been focused on the concept
of a boundary or transitional state
between normal aging and AD, or
less specifically, dementia. It is
now believed that the onset of AD
is commonly preceded by an in-
terim phase known as "mild
cognitive impairment" (MCI).2
Several descriptors, such as incipi-
ent dementia, isolated memory
impairment, and questionable
dementia have been coined, re-
flecting an attempt by investi-
gators to characterize a "pre-
clinical phase"-a transitional
state between normal aging and
the earliest stage of cognitive im-
pairment. 3 MCI appears to be a
signal of disease onset that can
help target individuals for early in-
terventions. Researchers and
clinicians are pinning their hopes
on the chance that identifying and
treating this preclinical phase can
halt the progression toward AD.
"Normal" Forgetfulness
Versus MCI
The boundaries between the cog-
nitive changes of aging and
MCI-as well as MCI and mild
AD-are not very well delineated.
The primary distinction between
normal adults/control subjects
and subjects with MCI is in the
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area of memory without impair-
ment of other cognitive functions
such as language, perception,
motor skills, and judgment. In
clinic, I often come across older
adults and their families who be-
lieve that memory impairment is
part of aging, and I am sure some
of you may ask, "Where does nor-
mality end and abnormality
begin?" Since there is no firm de-
marcation, the concept of a
transitional phase becomes even
more important.
Most studies have found that
cognition does not decline in most
older adults. Cognitive deficits are
often a consequence of a clinical or
subclinical disease process. There is
association among disease, func-
tional impairment, social disen-
gagement, and cognitive impair-
ment. There is age-related mild
slowing in the speed of thought
processing, particularly in process-
ing parallel thoughts. A mild and
benign difficulty in remembering
names of individuals on meeting
them, misplacing keys and spec-
tacles, or difficulty in remembering
infrequently used phone numbers
may represent an age-related
change. Such a change does not rep-
resent a sharp, severe, or persistent
decline from a previous level and
does not interfere with an
individual's day-to-day functioning.
Several factors need to be kept
in mind when assessing an
individual's memory and learning.
These include hearing or visual
deficits, general medical condi-
tions, use of medications, motor
deficits, educational background,
living arrangements, and cultural
concepts of aging. In addition,
depression, being common in old
age, is associated with social iso-
lation and can be an underlying
cause of cognitive decline.
Despite controversies regard-
ing how to clearly characterize
those who have normal age-
related forgetfulness and those
with MCI, most experts recognize
the importance of making this dis-
tinction. Subjects with MCI in
contrast to normal individuals
show impairment in a test of
memory called "delayed recall."
(An individual is provided some
information and is asked to recall
it after five minutes.) There is vast
agreement that a significant de-
cline in "verbal episodic memory"
(memory of specific events such
as phone messages and appoint-
ments) is the earliest and most
sensitive sign of incipient AD at
the preclinical stage.
As mentioned earlier, other
cognitive abilities, such as lan-
guage, motor skills, and executive
functions, are spared. Having the
ability to perform activities of
daily living such as driving a car
or balancing a checkbook-and
not having other cognitive defi-
cits-may make it difficult for an
individual with MCI to be identi-
fied. The memory loss that
distinguishes healthy adults from
those thought to have MCI or
preclinical AD is abnormal for
the individual's age and level of
education.
Transition from MCI
To Dementia
Dementias are described as cog-
nitive disorders involving impair-
ment of memory with deficits in
language, abstract thinking, atten-
tion, orientation, and judgment.
AD is the most common form of
dementia, 4 which increases in
prevalence thirty to fifty percent
by age eighty-five. AD, like MCI,
is characterized by memory im-
pairment. However, unlike MCI,
memory impairment is not suffi-
cient to make a diagnosis of
probable AD. According to
American Psychiatric Asso-
ciation's classification,' probable
AD is characterized by a progres-
sive memory impairment that is
not from a psychiatric, general
medical, or substance use disor-
der. Such deterioration is
accompanied by deficits in at least
one other mental function such as
perception (agnosia), language
(aphasia), or a motor skill
(apraxia). In addition, these defi-
cits are severe enough to interfere
with an individual's social and oc-
cupational functioning.
Let's think of it this way: Some
of us, at some point, will develop
mild cognitive impairment, which
will be characterized by significant
memory impairment for our age
and educational level. Some-but
not all-of those individuals will
progress towards AD. An encour-
aging finding for those who see
the glass as half full: MCI, or a
preclinical phase, is detectable up
to seven years before someone
meets established criteria for AD. 6
We also know that an average
delay in diagnosis of AD is about
two years, which allows us a win-
dow of opportunity if we could
develop reliable markers/methods
to identify susceptible individuals
and nip progression in the bud.
My review of literature sug-
gests that not all individuals
diagnosed with MCI develop AD,
as one study in particular showed
that a small number of patients
remained cognitively stable even
after four years of observation. In
any case, it is true that people with
MCI have an increased risk of
progressing to AD approximately
at a rate of ten to twelve percent
per year, in contrast to normal
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adults, who convert at a rate of
one to two percent per year. Ef-
fective interventions are urgently
needed, considering that thirty-
eight percent of the middle- and
older-aged adults fulfill criteria for
MCI. 7 It is heartening to know
that many pharmacological agents
aimed at delaying cognitive de-
cline are readily available. In
addition, numerous clinical trials
by the National Institute of Health
and the pharmaceutical industry
are underway.
Why Break Bad News Early?
Some experts have questioned the
view that older individuals with
some susceptibility (e.g. family
history) should be screened regu-
larly, even before they have
demonstrated any symptoms.
Another concern is whether to
break bad news early when we are
not able to stop the decline. Cer-
tainly, at this juncture, medical
science has not had an unlimited
success in its effort to prevent or
treat the decline once it has
started. But we do have a window
of opportunity-lasting several
years-to attempt to intervene in
order to improve quality of life for
patient and caregivers.
Those of us who argue in fa-
vor of identifying susceptible
individuals at the earliest possible
stage insist that even at the milder
stages of the disease, patients re-
tain significant functions and can
play an active role in planning and
preparing for their future needs.
Decisions such as healthcare
proxy, power of attorney, and
advance directives can be made-
preferably while an individual is
fully involved. A timely diagnosis
removes the uncertainty about the
cause of cognitive decline, which
allows family to avoid enormous
stress and strained relationships
resulting from blame and denial.
An early diagnosis allows educa-
tion of caregivers in a timely
manner regarding patient safety
and handling. Caregivers also
need to plan their lives as they
anticipate increased physical and
emotional demands.
From a clinical point of view,
an early assessment allows evalu-
ation for other reversible and
treatable causes of memory im-
pairment. In addition, families
and their caregivers may elect to
have certain experimental and in-
vestigational treatments available
to retard progression of MCI, al-
though conclusive evidence
regarding these treatments must
await results of clinical trials in
progress.
Clinical Evaluation for MCI
A diagnostic test or marker that
would distinguish patients with
MCI from normal older adults,
and those with early AD, is not
available at this time. Clinicians
often find themselves confronted
by patients in this "no man's
land" between normal aging and
dementia. In the absence of a di-
agnostic test, we use criteria and
guidelines that have been devel-
oped for research and clinical
evaluations. A commonly used set
of criteria, developed by research-
ers at Mayo Clinic, includes...
(a) complaint of memory
problems either by pa-
tient, family, or referring
physician;
(b) memory deficit abnormal
for age and education;
(c) no evidence of difficulty in
carrying out activities of
daily living and other cog-
nitive functions; and
(d) these individuals do not
meet criteria for AD.8
Most adults who suspect
some memory problems would
generally seek help from their
primary-care physicians, who
may elect to do preliminary assess-
ment and then obtain a con-
sultation with colleagues who are
trained in diagnosing such dis-
orders. In either event, the in-
volvement of a knowledgeable
informant is crucial and worth the
effort. Spouses and other adults
in the family sometimes make very
important observations regarding
patients' memory changes and re-
sultant impact on functioning
providing a sensitive indicator of
illness.
An assessment for MCI in-
cludes a detailed personal and
family history, a physical examina-
tion, and a review of daily
self-maintenance functions. These
include such daily tasks as dress-
ing, eating, toileting, house-
keeping, shopping, accounting,
food preparation, and transporta-
tion. A diagnostic evaluation also
includes laboratory tests such as a
blood picture to look for anemia
or infection; tests for liver and thy-
roid functions; levels of vitamin B12
and folic acid; and tests for diseases
such as syphilis or HIfV. In suspected
cases where no other cause could
be found, a CAT scan or MRI of
the head is recommended, which
helps to exclude certain neurologi-
cal illness and to identify the
severity of brain shrinkage (atro-
phy). Specialized tests such as
SPECT scan and APOE genetic typ-
ing are performed at few research
centers, and are not part of routine
evaluations.
Available Treatments
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The first step in treatment is al-
ways to provide education and
support to affected individuals
and caregivers regarding available
options. By "treatment," we of-
ten mean pharmacological
interventions-but these are only
part of the treatment plan. As
many of you may know or may
have read, several pharmacologi-
cal agents that enhance memory
and slow cognitive decline are
being used in treatment of mild
to moderate AD. Most widely
used agents are called cholinest-
erase inhibitors, as they increase
the level of the neurotransmitter
acetylcholine by inhibiting its de-
struction. These agents include
donepezil, rivastigmine, and
galantamine. I must point out that
these medications have not yet
been approved by the Food and
Drug Administration for treat-
ment of MCI. Several large-scale
trials are underway to assess the
efficacy of these agents in this par-
ticular disorder. At the same time,
many physicians consider it a
standard of care to offer these
agents, in combination with vita-
min E, to their patients with MCI.
Other interventions that are be-
ing used or tested include
melatonin, gingko biloba, and
anti-inflammatory agents such as
rofecoxib and celecoxib.
Summary
Memory is an integral part of our
survival; it allows us to learn and
respond to our environment. Di-
agnosis and prevention of
predictors of dementia, or specifi-
cally Alzheimer's disease, has
become a focus of geriatric re-
search. Mild cognitive impairment
is one of those potential predic-
tors, and we hope that by
instituting effective strategies at
this early stage, we would lessen
the tremendous toll on affected
individuals, their families, and our
society.
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